PREMM Trademark

Trademark Overview

On Tuesday, April 11, 2017, a trademark application was filed for PREMM with the United States Patent and Trademark Office. The USPTO has given the PREMM trademark a serial number of 87406871. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Tuesday, December 12, 2023. This trademark is owned by Dana-Farber Cancer Institute, Inc.. The PREMM trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

clinical risk assessment services in the nature of genetic testing for medical purposes based on genetic predictions in the field of cancer susceptibilities
premm

General Information

Serial Number87406871
Word MarkPREMM
Filing DateTuesday, April 11, 2017
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateTuesday, December 12, 2023
Registration Number5472974
Registration DateTuesday, May 22, 2018
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 6, 2018

Trademark Statements

Certificate of Correction for RegistrationIn the statement, line 1, "CORPORATION" should be deleted, and "NON-PROFIT CORPORATION" should be inserted.
Goods and Servicesclinical risk assessment services in the nature of genetic testing for medical purposes based on genetic predictions in the field of cancer susceptibilities

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 18, 2017
Primary Code044
First Use Anywhere DateThursday, August 31, 2006
First Use In Commerce DateThursday, August 31, 2006

Trademark Owner History

Party NameDana-Farber Cancer Institute, Inc.
Party Type30 - Original Registrant
Legal Entity Type54 - NOT AVAILABLE
AddressBoston, MA 02215
Party NameDana-Farber Cancer Institute, Inc.
Party Type20 - Owner at Publication
Legal Entity Type54 - NOT AVAILABLE
AddressBoston, MA 02215
Party NameDana-Farber Cancer Institute, Inc.
Party Type10 - Original Applicant
Legal Entity Type54 - NOT AVAILABLE
AddressBoston, MA 02215

Trademark Events

Event DateEvent Description
Monday, January 22, 2024NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Tuesday, January 16, 2024NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Tuesday, December 12, 2023NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Tuesday, December 12, 2023REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, December 12, 2023CORRECTION UNDER SECTION 7 - PROCESSED
Tuesday, December 12, 2023CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, June 14, 2023TEAS SECTION 8 & 15 RECEIVED
Wednesday, June 14, 2023TEAS SECTION 7 REQUEST RECEIVED
Monday, May 22, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, February 10, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, February 10, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 22, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, March 6, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 6, 2018PUBLISHED FOR OPPOSITION
Wednesday, February 14, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, January 29, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 29, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 29, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 29, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 10, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 25, 2018ASSIGNED TO LIE
Friday, January 12, 2018TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, January 10, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 10, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 10, 2017NON-FINAL ACTION E-MAILED
Monday, July 10, 2017NON-FINAL ACTION WRITTEN
Wednesday, July 5, 2017ASSIGNED TO EXAMINER
Tuesday, April 18, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

premm genetic based predictions field susceptibilities cancer purposes testing assessment risk